Adlai Nortye Ltd

Research Adlai Nortye Ltd (ANL) on Bullrun: market cap USD 734.78M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerANL
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 734.78M
• Financial periodQ4 2025
• RevenueUSD 5.00M
• Net income-USD 35.53M
• Free cash flow-USD 33.64M

Valuation Snapshot

latest market cap is USD 734.78M.

About Adlai Nortye Ltd

Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rectal cancer.

Frequently asked questions

What is Adlai Nortye Ltd's market cap?

Adlai Nortye Ltd's market capitalization is USD 734.78M.

What does Adlai Nortye Ltd do?

Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products.